

Case report

Open Access

Long-term remission of myopic choroidal neovascular membrane after treatment with ranibizumab: a case report

Neruban Kumaran*, Dawn A Sim and Adnan Tufail

Address: Department of Medical Retina, Moorfields Eye Hospital, London, UK

Email: Neruban Kumaran* - neruban@doctors.org.uk; Dawn A Sim - dawnsim@doctors.org.uk; Adnan Tufail - adnan.tufail@moorfields.nhs.uk

* Corresponding author

Published: 28 October 2009

Received: 28 October 2009

Journal of Medical Case Reports 2009, **3**:84 doi:10.1186/1752-1947-3-84

Accepted: 28 October 2009

This article is available from: <http://www.jmedicalcasereports.com/content/3/1/84>

© 2009 Kumaran et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction: Myopia has become a big public health problem in certain parts of the world. Sight-threatening complications like choroidal neovascularisation membranes occur in up to 10% of pathological myopia, and natural history studies show a trend towards progressive visual loss. There are long-term financial and quality-of-life implications in this group of patients, and treatment strategies should aim for long-term preservation of vision.

Case presentation: A 56-year-old Caucasian woman presented with a best-corrected visual acuity of 6/6-l in her right eye and 6/24 in her left. Fundal examination revealed pathological myopia in both eyes and an elevated lesion associated with pre-retinal haemorrhage in the left macula. Ocular coherence tomography and fundus fluorescein angiogram confirmed a subfoveal classic choroidal neovascularisation membrane. The patient decided to proceed with intravitreal ranibizumab (0.5 mg) therapy. One month after treatment, best-corrected visual acuity improved to 6/12 in her left eye, with complete resolution subretinal fluid on ocular coherence tomography. After three months, best-corrected visual acuity further improved to 6/9, which was maintained up to 16 months post-treatment.

Conclusion: We suggest intravitreal ranibizumab as an alternative treatment for long-term remission of myopic choroidal neovascular membrane. It also suggests that myopic choroidal neovascularisation membranes may require fewer treatments to achieve sustained remission. Furthermore, this could serve as a feasible long-term management option if used in conjunction with ocular coherence tomography.

Introduction

In certain parts of the world, myopia has reached epidemic proportions and is now a major public health problem [1]. The prevalence of high and pathological myopia appears to be rising in Asia and other parts of the world. This has a large public health impact because of the associated increase in potentially blinding ocular complications. High myopia or myopia with increased risks of ocular morbidity can be defined as a spherical equivalent

of at least -6 OD. The resulting ocular pathology is usually due to excessive elongation of the eyeball and associated with pathological changes in the fundus [2].

Myopia accompanied by degenerative changes in the sclera, choroid, retinal pigment epithelium and associated compromises in visual function have also been termed 'degenerative', 'malignant' and 'pathological' [3].

Many complications and associations have been noted with such 'pathological' myopia. Evidence from both clinic and population-based studies suggest that high and low myopia in European and Afro-Caribbean populations [4,5] may be associated with cataract (posterior subcapsular, nuclear and occasionally, cortical cataract), the leading cause of blindness in the world [6].

Myopic eyes are known to have longer axial lengths and vitreous chamber depths compared to emmetropic eyes. Eyes with longer axial lengths tend to have higher cup-disc ratios, increased optic nerve fibre layer defects and possibly greater deformity of the lamina cribrosa, leading to high susceptibility to glaucomatous optic disc changes [7]. Such elongation may lead to mechanical stretching and thinning of the choroid and retinal pigment epithelium and other vascular degenerative changes. These changes include choroidal neovascularisation, macular holes, chorioretinal atrophy, Fuchs' spots, lacquer cracks, lattice degeneration and retinal breaks. Here, we describe the presentation, follow-up and management of a myopic patient who presented with a choroidal neovascular membrane (CNVM), as a result of choroidal neovascularisation (CNV).

Case presentation

A 56-year-old Caucasian woman with high-myopia (-6.00) presented with a one month history of sudden, painless distortion of vision in her left eye. She noted that reading had been more difficult for the last two weeks. Previous documented best corrected visual acuity (seven years ago) was 6/5 in the right eye and 6/6 in the left eye. Previous ocular history of note was macular change secondary to myopia, diagnosed by her optician eleven years previously. Both of her parents were myopic, but her medical history was otherwise unremarkable.

On examination, best-corrected visual acuities were 6/6-1 in the right and 6/36, improving to 6/24 with pinhole, in the left eye. The left eye was noticed to have an Adie (tonic) pupil. Both anterior segments were deep and quiet and the intraocular pressure was 16 mmHg in each eye.

Examination of the left fundus revealed a myopic, tilted disc and staphyloma and an elevated grayish lesion associated with small pre-retinal haemorrhage. The vitreous was quiet and retinal vessels were of normal calibre (Figure 1). Ocular coherence tomography (OCT) showed no sub-retinal fluid but did reveal a choroidal neovascular membrane (CNVM). Fundus fluorescein angiogram (FFA) showed a classic subfoveal CNVM, with early, well-defined hyperfluorescence (Figure 2) and late leakage. Therefore, the drop in the vision of her left eye was attributed to the development of a CNVM. Myopic changes



Figure 1
Colour fundus photo of the left eye with myopic macular degeneration, atrophy and an elevated greyish lesion with associated pre-retinal haemorrhage.

were seen in the right eye but it was otherwise unremarkable.

After considering discussion of various treatment options, the patient decided to proceed with 0.5 mg of intravitreal ranizumab (Lucentis). One month following intravitreal injection into the left eye, her visual acuity improved from 6/32 to 6/12. OCT and FFA showed no subretinal fluid and furthermore regression of CNVM complex (Figure 3). However, the patient still complained of distortion and that the images are still smaller and darker in the left eye compared to the right eye.




Figure 2
Early phase fundus fluorescein angiogram showing choroidal neovascular membrane with well defined hyperfluorescence.




Figure 3
Fundus fluorescein angiogram showing regression of the choroidal neovascular membrane complex.

Three months post-treatment, her visual acuity in the left eye was 6/18, improving to 6/12 with pinhole. She noticed further improvement in left reading vision. The patient re-presented four and a half months post-treatment with new distortion in the left eye. FFA showed a small area of new leakage away from the centre of vision. It was decided to withhold further treatment at that time as her visual acuity was 6/12, improving to 6/9 with pinhole, which remained stable for 16 months. The patient agreed to monitor for any changes with an Amsler chart. VA and OCT findings in her subsequent follow up appointments were stable up to one year after treatment with Lucentis.

Discussion

Choroidal neovascular membrane is one of the leading causes of severe visual loss. Usually a manifestation in the elderly, it is often associated with age-related macular degeneration. In this case, however, it is as a cause of the myopia of the patient.

It appears the balance between antiangiogenic factors (e.g., pigment epithelium derived factor) and angiogenic factors (e.g. vascular endothelial growth factor or VEGF) determines the growth of CNV and VEGF has been temporally and spatially correlated with the development of CNV [8].

The main treatment options for CNV are photodynamic therapy, surgery and anti-vascular endothelial growth factor (anti-VEGF) treatment.

VEGF was isolated in 1989 [9] and VEGF-A is now known to promote growth of vascular endothelial cells from

arteries, veins and lymphatics and is needed as a survival factor for vascular endothelial cells [10]. Eventually, in 2005 VEGF-A, a known mediator of tumour angiogenesis, was documented to have a key role in the development of the choroid vasculature. Examples of VEGF inhibitors include pegaptanib (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).

The use in myopic CNVM of intravitreal bevacizumab (Avastin), a cheaper and closely related alternative to ranibizumab, has been reported in both retrospective [11,12] and prospective studies [13,14], with the majority of patients achieving CNVM remission and improvement in visual acuity. Currently, bevacizumab is the mainstay of management both as a mono-therapy and as an adjuvant to PDT. Furthermore, although bevacizumab appears to be a safe and effective treatment for myopic CNVM, follow-up periods have been relatively short, ranging from 35 days to seven months and long-term outcome is unknown.

In 2008, Silva *et al.* conducted a retrospective, non-randomized interventional case series study on the short term efficacy and safety of intravitreal ranibizumab for myopic CNV. A significant mean improvement in VA was noted at one, three and six months, with a significant reduction in mean central retinal thickness, as seen on OCT [15]. In addition, in 2009 a prospective study of 31 newly diagnosed patients showed a similar improvement in VA, in non-AMD related CNV with a mean follow up of 13.4 months [16]. Treatment of myopic CNVM with intravitreal ranibizumab with a 16-month-follow-up has not previously been reported in the literature. The prohibitive cost of ranibizumab has led to widespread use of bevacizumab.

Our patient had treatment with ranibizumab (Lucentis). Ranibizumab was developed due to questions over the ability of intravitreally injected molecules to penetrate across the retinal layers and reach the choroid.

The safety and efficacy of ranibizumab in the treatment of neovascular AMD have been evaluated in two large phase III, multicenter, randomized, double-masked, controlled pivotal trials, including different neovascular AMD patient populations.

The MARINA trial randomized 716 subjects in the United States with CNV to one of three treatment arms: monthly placebo injections, monthly intravitreal injections of 0.3 mg of ranibizumab, or monthly intravitreal injections of 0.5 mg of ranibizumab.

The ANCHOR trial randomized 423 subjects in the United States, Europe, and Australia who had CNV to one of three treatment arms: verteporfin photodynamic ther-

apy with monthly placebo ocular injections, monthly intravitreal injections of 0.3 mg of ranibizumab with a placebo photodynamic therapy procedure, and monthly intravitreal injections of 0.5 mg of ranibizumab with a placebo photodynamic therapy procedure.

Analyses of these two phase III studies (ANCHOR and MARINA trials) indicate that ranibizumab results not only in a slowing down of vision loss but also a clinically meaningful vision gain at the primary 12-month assessment in a significant proportion of patients. In the case of the MARINA study these benefits were also observed through the final 24-month assessment [17].

In 2007 an open-label single centre prospective study called the prospective OCT imaging of patients with neovascular AMD Treated with intra-ocular Lucentis (PrONTO) was designed to investigate the role of OCT in guiding retreatment decisions for a variable dosing regimen in patients with choroidal neovascularisation (CNV) secondary to AMD. The aim of the study was to find out if an OCT-guided treatment regimen could be used to maintain improvements in visual acuity over two years after three consecutive monthly doses of Lucentis (500 µg) [18].

The results showed rapid improvements in visual acuity and OCT measurements. After 12 and 24 months, outcomes in the study were similar to the MARINA and ANCHOR phase III study results. It is worth noting that the mean frequency of dosing reduced by more than half. Based on these results, OCT appears to be a useful tool for guiding retreatment decisions such as the frequency of treatment of patients with CNV. However a prospective, randomized clinical trial is needed to confirm these results [18].

Conclusion

In conclusion, we presented a patient with myopic CNVM whose vision improved and stabilized at 6/6 after one treatment of ranibizumab (Lucentis). Furthermore, a review of major trials that have been done on CNV show that ranibizumab in CNV not only reduces loss of vision but in fact results in visual gain. In addition, the PrONTO trial shows that the frequency of treatment should be guided by investigations such as OCT and the treatment tailored to the individual findings in the patient (such as an increase in central retinal thickness of 100 µm or more on OCT.) This is further supported by studies showing the use of intravitreal anti-VEGF resulting in long term remission of other Type 2 CNVM.

Due to the relative rarity of myopic CNVM, there is lack of evidence for intravitreal anti-VEGF treatment. Treatment of CNVM should therefore be individualized and the

chance of spontaneous resolution discussed with patients. This case report presents intravitreal ranibizumab as a reasonable treatment option, and shows that the frequency of treatment can be modulated according to OCT findings.

Abbreviations

CNV: choroidal neovascularisation; CNVM: choroidal neovascular membrane; OCT: ocular coherence tomography; FFA: fundus fluorescein angiogram; VEGF: vascular endothelial growth factor.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

DS reviewed the patient in clinic. AT and DS structured the management plan and followed up the patient. NK and DS reviewed the article for intellectual content while NK carried out a literature review. NK and DS read and approved the final script.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the journal's Editor-in-Chief.

References

- Grosvenor T: **Why is there an epidemic of myopia?** *Clin Exp Optom* 2003, **86**:273-275.
- Goldschmidt E: **Ocular morbidity in myopia.** *Acta Ophthalmol Suppl* 1988, **185**:86-87.
- Duke-Elder S: **Pathological refractive errors.** *System of Ophthalmology.* St. Louis, Mosby 1970, **V**.
- Leske MC, Wu SY, Nemesure B, Hennis A, Barbados Eye Studies Group: **Risk factors for incident nuclear opacities.** *Ophthalmology* 2002, **109**:1303-1308.
- Saw Seang-Mei, Gazzard Gus, Shih-Yen Edwin Chan, Chua Wei-Han: **Myopia and associated pathological complications.** *Ophthalmic & physiological optics: the journal of the British College of Ophthalmic Opticians (Optometrists)* 2005, **25**(5):381-391.
- Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokarel G, Mariotti S: **Global data on visual impairment in the year 2002.** *Bull World Health Organ* 2004, **82**:844-851.
- Fong DS, Epstein DL, Allingham RR: **Glaucoma and myopia: are they related?** *Int Ophthalmol Clin* 1990, **30**:215-218.
- Bhatt NS, Diamond JG, Jalali S, Das T: **Choroidal neovascular membrane.** *Indian J Ophthalmol* 1998, **46**(2):67-80.
- Ferrara N, Henzel WJ: **Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.** *Biochem Biophys Res Commun* 1989, **161**:851-858.
- Ferrara N, Damico L, Shams N, Lowman H, Kim R: **Development of Ranibizumab, and anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.** *Retina* 2006, **26**:859-870.
- Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS: **Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.** *Br J Ophthalmol* 2007, **91**:157-160.
- Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, Oshima Y, Kusaka S, Tano Y: **Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.** *Br J Ophthalmol* 2007, **91**:161-165.

13. Chan WM, Lai TY, Liu DT, Lam DS: **Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.** *Ophthalmology* 2007, **114(12)**:2190-2196.
14. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Ares S, Lopez-Lopez F, Rodriguez M, Fernandez M: **Intravitreal bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: 1 year outcome.** *Br J Ophthalmol* 2009, **93**:448-451.
15. Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosa A, Carvalheira F, Abreu JR, Cunha-Vaz JG: **Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization.** *Retina* 2008, **28(8)**:1117-1123.
16. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A: **Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.** *Graefes Arch Clin Exp Ophthalmol* 2009, **247(3)**:311-318.
17. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group: **Ranibizumab for neovascular age-related macular degeneration: 2-year results of the MARINA study.** *N Engl J Med* 2006, **355(14)**:1419-1431.
18. Grossniklaus HE, Green WR: **All About PrONTO: Study Yielded Good Results in AMD With Treatment Guided by OCT MAY/JUNE.** *Retina Today* 2007:41-48.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

